Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative DCX and RUNX3 Methylation in Gastric and Lower Esophageal Adenocarcinoma
NCT00674167Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- May 2007
- Primary completion
- Dec 2015
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cisplatin, capecitabine in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by National University Hospital. Status: unknown.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00674167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00674167.